Bibliography
- BERNARDELLI P, GAUDILLIERE B, VERGNE F: To market, to market - 2001. Ann. Rep. Med. Chem. (2002) 37:257–277.
- DOHERTY AM: To market, to market — 2002. Ann. Rep. Med. Chem. (2003) 38:347–374.
- LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev (1997) 23:3–25.
- LIPINSKI CA: Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Tox. Meth. (2000) 44:235–249.
- HORSPOOL KR, LIPINSKI CA: Enabling strategies: advancing new drug delivery concepts to gain the lead. Drug Del. Tech. (2003) 3(7):34–46.
- FECHNER J, IHMSEN H, HATTERSCHEID D et al.: Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI-15715 in volunteers. Anesthesiology (2003) 99:303–313.
- SCHYWALSKY M, IHMSEN H, TZABAZIS A et al.: Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI-15715 in rats. Eur: Anesthesiol.(2003) 20:182–190.
- GUSTAFSSON D: Oral direct thrombininhibitors in clinical development. J. mt. Med. (2003) 254:322–334.